{"name":"Binghe Xu","slug":"binghe-xu","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQR3RNanRCQXNnWHNfVEt3dzFWQ1R6cGRiLVRwNjVXSVE1ZDVXdHl0X0ZzTC1WcUpKb0FmeEYwalZaS3RxZDJhS2tLY3d5YlhhMnFlNnk3aWd1aXhJOHlIZi1jZ3RJeHB1cVVqYjhNUHZua2M4Y21ZaXl0VkpLeURVbnFPS2tqcDRWVURNMTN1MTYtZnprb014N21iMnFZNndWRWQ0ZkhoZ3NpMWhkR0syU0JnblRwN1RKYWwxclo5WExtV1FRX1dEUWNwelBhTFEwcXNlVHIwTQ?oc=5","date":"2026-02-15","type":"trial","source":"BioPharma APAC","summary":"Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer - BioPharma APAC","headline":"Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5uOTFFcFB1WHlJS20zUFRpVU4wdDduVERJczhjV1VkMC1jVGZIa3RTaWdoLXRmcGE1dFB1cGZSYUIyVmRGX3c5Y0xaYmdsUWJyTFE0TUFNOEhISFVDSk9r?oc=5","date":"2024-10-01","type":"trial","source":"nature.com","summary":"metastatic breast cancer: the randomized phase 3 EVER-132-002 trial - nature.com","headline":"metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNcjA1M1NPUXh1Q2hxaVZVUmp4UTVoTmRZaUdCNTJuZlJsZ0Y5Qmw0dWYxXzY2WHlLdDVsUy0tMWFvVUF4T2lNcmxiUXVIczk4RE9LS19kdHdrQ0ZPSTF3S2NuNEw2NW42ck1qREhzSU0ydU5zN1Y5MDRoaUowdlFWZHhyX1kwTnI4aThzM3Fpd25sQWNTQ1ZabjViRG1GS2xSZUxOXzhBWG5KZTA5QURpTmRKLUF5RGhtaF85Y29sRVBzSFBnNnZHbnM5TmR1cXZ0Qm5tRE9iNWpDZmFN?oc=5","date":"2024-09-29","type":"trial","source":"PR Newswire Asia","summary":"Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress - PR Newswire Asia","headline":"Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1IYlBGZGc3REdzdFd5Mks1UDYwck9OTjlHSFFSVlRJTURyY1dDMmdiR0pQd0F2Q2F2a3VkTWRvZnM4NFpfQ0liNEhGOV94VjhtaDZpaGxYSXhLWFN0R19Z?oc=5","date":"2024-06-17","type":"trial","source":"nature.com","summary":"HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial - nature.com","headline":"HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFAxbEViTFRrYzQ1MzdwalVxcWZXSnVubzV6aDctQjVuSTJyeWcyZUhmaDhwYVJlcURwZnpXODNhYXlRalo4bENKQS1ob3RxNllvemRFa1VQLWJUWl9YSElUM2xWWFpiUGwta2o4UQ?oc=5","date":"2023-03-27","type":"trial","source":"Wiley Online Library","summary":"Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial - Wiley Online Library","headline":"Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFByMzVtS0d4dzdrVkNCNTVtdzFrQk5ua0dCS3E1T2JubmtlcW4wdXVPQ01RdWpKVkU3TUJzZkk3SEM2djNocklOcVBHdHlscElsQlUwbEl3LUpockM2MGtjQmNDZk10N28?oc=5","date":"2021-12-10","type":"pipeline","source":"MedPage Today","summary":"Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer - MedPage Today","headline":"Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE92OVFldF9wYnlWcmFNV2NRNFBraUVNeFJWcldBWXpEdVF5NFhLRWJoVDVEdzVzUFRHTjF1aXUzemJ6RExwZWU4ZXhsMF9HMFlDSllqZk80QWZsUE1Oa1hhOQ?oc=5","date":"2017-06-04","type":"pipeline","source":"NEJM","summary":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation - NEJM","headline":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}